Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, the company's immunotherapy treatment for different cancers. The plant will ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...